Dr. Stephanie King -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Stephanie King, a Internal Medicine physician based in Los Angeles, CA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Stephanie King has received $114,032.27 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Stephanie King has received a total of $114,032.27 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $114,032.27 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Stephanie King's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Ownership Interest$114,032.27Ownership stakes, dividends, and investment returns

The largest payment category for Dr. Stephanie King is Ownership Interest, accounting for 100% ($114,032.27) of total pharmaceutical payments received. This indicates a financial ownership interest in a pharmaceutical or medical device company.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Stephanie King. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Pfizer Inc$114,032.271

Dr. Stephanie King has a financial relationship with Pfizer Inc, receiving $114,032.27 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Stephanie King's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Stephanie King has received $114.0K across 1 pharmaceutical payments as a Internal Medicine physician in Los Angeles, CA. Top paying companies include Pfizer Inc ($114.0K). Dr. King received a single, substantial payment of $114,032, which represents 100% of her reported pharma payments. This entire amount is attributed to an 'ownership' payment from Pfizer Inc., indicating a potential financial stake rather than service-based compensation. The data reflects only one payment in 2025, suggesting this might be an initial or isolated transaction.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Stephanie King is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

When consulting with a physician, consider asking about the nature of any financial relationships they have with pharmaceutical companies, especially if they involve ownership or significant investments. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Stephanie King Compares to Other Internal Medicine Physicians

For Internal Medicine specialists, payment profiles vary widely, with some receiving numerous smaller payments for services and others having fewer, larger transactions related to investments or ownership.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Stephanie King in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Pfizer Inc$114,032.27ownershipN/A2025-08-08Not Assessed

Frequently Asked Questions About Dr. Stephanie King's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Stephanie King received?

Stephanie King has received a total of $114.0K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Stephanie King taking too much pharma money?

Stephanie King has received $114.0K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Internal Medicine), the types of payments, and how they compare to peers. The largest payment category is ownership ($114.0K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Stephanie King?

The top pharmaceutical companies paying Stephanie King are: Pfizer Inc ($114.0K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Stephanie King receive?

Stephanie King's payments by type: ownership: $114.0K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Stephanie King's payments compare to other Internal Medicine doctors?

To compare, look at the total amount ($114.0K), number of payments (1), and the types of payments received. Internal Medicine physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Stephanie King's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1603305653). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Stephanie King's pharma payment profile?

The concentration of payments from a single company (Pfizer Inc.) and a single payment type (ownership) is notable. Stephanie King has received $114.0K in total pharma payments.

How does Stephanie King compare to peers in Internal Medicine?

For Internal Medicine specialists, payment profiles vary widely, with some receiving numerous smaller payments for services and others having fewer, larger transactions related to investments or ownership.

Are Stephanie King's pharma relationships typical for Internal Medicine?

The high average payment amount is driven by this single, large ownership transaction.

What should patients of Stephanie King know about these payments?

When consulting with a physician, consider asking about the nature of any financial relationships they have with pharmaceutical companies, especially if they involve ownership or significant investments.

What patterns are visible in Stephanie King's payment history?

The limited number of payments (one) makes it difficult to establish a consistent payment trend.

Understanding This Doctor Payment Report

This transparency report for Dr. Stephanie King is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Stephanie King's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Stephanie King and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.